Two experts propose replacing Phase 3 trials with smaller, faster alternatives and post-market surveillance to invigorate the pharmaceutical industry.
Advertisement
The Scientist
Most Recent
Although fully organized patient-run trials are still few and far between, patients are taking a more active role in clinical research.
Patients are sidestepping clinical research and using themselves as guinea pigs to test new treatments for fatal diseases. Will they hurt themselves, or science?
The FDA approves an antibody-drug conjugate that effectively treats a certain type of advanced breast cancer with fewer side effects than previous drugs.
The first human trial of a treatment using induced pluripotent stem cells has received conditional approval from an institutional review board in Japan.
A retinal prosthesis, already available in Europe, can restore partial sight to people with a genetic disorder that causes blindness.
Tuberculosis bacteria find shelter from drugs and the body’s defenses in bone marrow stem cells.
One of the most advanced tuberculosis vaccines has failed to protect infants from getting the disease in a clinical trial, but it may be effective in adults.
Using a SMART card containing your genetic information and medical history, you could one day soon be diagnosed and treated for all kinds of diseases at an ATM-style kiosk.
Follow The Scientist
Stay Connected with The Scientist
-
The Scientist Magazine
-
The Scientist Careers
-
Neuroscience Research Techniques
-
Genetic Research Techniques
-
Cell Culture Techniques
-
Microbiology and Immunology
-
Cancer Research and Technology
Current Issue
